Management of large-vessel vasculitis

Area of Science:

• Rheumatology
• Immunology
• Internal Medicine

Background:

• Large-vessel vasculitis, including giant cell arteritis (GCA) and Takayasu arteritis (TAK), is primarily treated with glucocorticoids.
• Glucocorticoid therapy is associated with significant toxicity and frequent disease relapses.
• The need for effective glucocorticoid-sparing agents has driven research into nonbiologic and biologic therapies.

Purpose of the Study:

• To review recent evidence on the management of GCA and TAK.
• To discuss the efficacy of nonbiologic and biologic glucocorticoid-sparing agents in large-vessel vasculitis.

Main Methods:

• Review of recent randomized controlled trials and observational studies.
• Analysis of clinical trial data for biologic agents in GCA and TAK.
• Evaluation of current unmet needs in the management of large-vessel vasculitis.

Main Results:

• Tocilizumab demonstrated efficacy as a glucocorticoid-sparing agent for GCA in a randomized trial.
• Trials involving tocilizumab and abatacept for TAK did not show significant improvement in relapse-free survival compared to placebo.
• Further clinical trials are planned for abatacept and ustekinumab in GCA, and rituximab and TNF inhibitors in TAK.

Conclusions:

• Biologic agents have shown potential in managing GCA, but their role in TAK requires further investigation.
• Significant unmet needs remain in large-vessel vasculitis management, including the need for well-designed trials, validated outcome measures, and standardized assessment methods.
• Identification of biomarkers to guide targeted treatment selection is crucial for advancing the care of patients with large-vessel vasculitis.